Download PDFPDF

Characteristics and publication fate of unregistered and retrospectively registered clinical trials submitted to The BMJ over 4 years
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    A valuable addition to the literature

    This paper is a very valuable addition to the literature on clinical trial transparency. It illustrates once again that self-regulation by the medical research sector does not work.

    One limitation is the data provided in the supplementary appendix. The authors could have listed the full information gathered on each trial, including trial number (where available), name of PI, and sponsor name. As the recent STAT investigation into unreported trials ( has shown, making performance transparent in and of itself can drive the subsequent adoption of best practices, which is in the interests of patients and the research community alike.

    Even if confidentiality agreements precluded the identification of trials, it may have been possible to include more granular data without enabling the re-identification of specific trials. For example, many countries and funders have laws, policies and regulations that make prospective trial registration compulsory (

    Knowing in which countries (rather than aggregated global regions) the unregistered and retrospectively registered trials were conducted, which funders (rather than aggregated funder types) funded them,...

    Show More
    Conflict of Interest:
    The autor is a campaigner committed to improving clinical trial transparency, and therefore has an interest in influencing institutional and national policies and outcomes.